Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check By Kevin Dunleavy Jan 29, 2025 9:01am Drug Prices Pfizer Collegium Pharmaceutical Novartis ...

Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 million to ...

UCB was a new entrant among the top 20 biopharmaceutical companies, doubling its market capitalisation from $16.9bn in 2023 to $38.7bn in 2024. Source: GlobalData, Pharma Intelligence Center; Stock ...

After hours: January 31 at 5:25:06 PM EST Loading Chart for ABVC ...

In recent years, the scale of biopharma investment into Ireland has accelerated, with some significant investments being made by the biggest companies in the industry. The country has always been ...

Europe to review safety data for Eisai-Biogen Alzheimer's drug Healthcare & Pharmaceuticalscategory· January 31, 2025 Indian biopharma company Biocon reported third-quarter revenue on Thursday ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...